Stay updated with breaking news from Acelyrin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acelyrin, Inc. (NASDAQ:SLRN – Get Rating) Director Beth C. Seidenberg acquired 60,000 shares of the firm’s stock in a transaction on Tuesday, May 9th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,080,000.00. Following the completion of the purchase, the director now directly owns 60,000 shares […]
Acelyrin, Inc. (NASDAQ:SLRN – Get Rating) major shareholder Biopartners Fund Ii Westlake acquired 1,250,000 shares of the stock in a transaction that occurred on Tuesday, May 9th. The stock was acquired at an average cost of $18.00 per share, with a total value of $22,500,000.00. Following the completion of the purchase, the insider now owns […]
Acelyrin, Inc. (NASDAQ:SLRN – Get Rating) Director Beth C. Seidenberg acquired 60,000 shares of the stock in a transaction dated Tuesday, May 9th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,080,000.00. Following the transaction, the director now directly owns 60,000 shares of the company’s stock, […]
Acelyrin, Inc. (NASDAQ:SLRN – Get Rating) insider Ronald Oyston purchased 1,000 shares of the company’s stock in a transaction dated Tuesday, May 9th. The shares were acquired at an average price of $18.00 per share, with a total value of $18,000.00. Following the transaction, the insider now owns 1,000 shares in the company, valued at […]
LOS ANGELES, May 9, 2023 /PRNewswire/ -- ACELYRIN, INC. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology,... | May 9, 2023